Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma/Payer Deals: 2011 Saw Important Step In Shift To Value-based R&D

Executive Summary

Three major drug makers inked broad alliances with the research departments of major US payers in 2011. The alliances signal that even as pharma reorients its R&D engines to be more flexible and externally focused in the hopes of shedding risk and cost, such moves are not enough.

Advertisement

Related Content

With Personalized Medicine, Payers Want A Role In Early Development
New Insurance Marketplaces Won’t ‘Move The Needle’ Near-Term For Pharma Economics – An Interview With Booz & Co.
Driving Rx Adherence In Value-Based Insurance Design Needs More Than Lower Copays – Harvard Researcher
Merck-Geisinger Collaboration Aims For “Pipeline” Of Treatment Adherence Tools
For Merck, Outcomes Trials Offer Fast Track To Payers
Deals Of The Week: Shire/Janssen, Pfizer/SFJ Pharma, AstraZeneca/IMS Health
AstraZeneca’s Real-World Outcomes Deal With IMS Aims To Turn Treatment Data Into Business Decisions
AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel